Gentian showcases diagnostic research at EuroMedLab 2025

Posters: Retinol-Binding Protein and NT-proBNP

At EuroMedLab 2025 in Brussels, Gentian Diagnostics will present two scientific posters showcasing our latest research:

• NT-proBNP (in development): A novel assay for improved detection and monitoring of heart failure

• Retinol-Binding Protein (RBP): An assay designed to support nutritional status evaluation and renal function assessment

Poster:
Addressing glycosylation bias in NT-proBNP testing

The poster 0356 "Development and characteristics of immunoturbidimetric NT-proBNP assay based on antibodies targeting glycosylation-free regions of NT-proBNP" focuses on Gentian’s novel approach to NT-proBNP quantification.

Current immunoassays use antibodies that bind to the central region of NT-proBNP, which is usually glycosylated. Glycosylation of NT-proBNP restricts the binding of the antibodies and detection of the protein. It has been shown that up to 80% of the circulating NT-proBNP may be glycosylated in the central region. Gentian’s proto-type assay is designed to overcome this underestimation by using antibodies targeting glycosylation-free regions of the molecule.

Key findings from the Gentian NT-proBNP proto-type assay study:

• Enzymatic deglycosylation by glycosidase treatment had no significant effect on measured values, confirming the assay detects total NT-proBNP regardless of glycosylation status
• Strong analytical performance with compatibility across major instrument platforms like Mindray and Beckman Coulter

Measuring NT-proBNP, independent of glycosylation status, potentially offers more accurate assessment of heart failure in diverse patient populations. Ongoing studies aim to further explore the clinical utility of this approach.

Poster:
Establishing a reference range for Gentian's RBP assay

In the poster 2423 "Establishment of a Reference Range for Gentian Retinol Binding Protein (RBP) Assay Using Beckman Coulter DxC 700 AU Analyzer", Gentian presents a comprehensive reference range study for its RBP assay.

RBP plays a dual role as a biomarker for vitamin A deficiency and renal dysfunction, making it valuable in both nutritional and nephrological assessments.

Highlights from the study:

• A reference range of 24–62 mg/L was established for the Gentian RBP assay, slightly broader than previously reported values
• Separate ranges were calculated for males (22–61 mg/L) and females (19–57 mg/L), suggesting potential sex-based differences warranting further analysis
• No significant differences were found between fresh and frozen samples, or between serum, lithium-heparin plasma, and EDTA plasma, confirming the assay’s robustness across sample types and storage conditions

These results underscore the importance of assay-specific reference validation to ensure accurate clinical interpretation of RBP levels.

Meet the Gentian team at booth #115

Visit us at booth #115 to learn more about our full range of diagnostic assays and ongoing scientific developments. Our team looks forward to connecting with laboratory professionals and clinicians interested in improving diagnostic workflows through high-quality, open-channel reagents.

To access the posters or speak with our scientists, please get in touch: